Table 7.
Review of occurrence of oliguria, dialysis requirement, mean time of peak serum creatinine, severity of renal failure, and death in the IV ribavirin-treated HFRS cohort vs. historical non-ribavirin-treated HFRS controls in Korea.
| Cohort | Oliguria, N (%) | Dialysis, N (%) | Mean day, peak Cr | Mean, peak Cr (mg/dl) | Death, N (%) | |
|---|---|---|---|---|---|---|
| Ribavirin | Rusnak (N = 34)a | 1/34 (3%)b | 0/34 (3%) | 6.8 | 3.46 | 1/34 (3%) |
| Rusnak (N = 38)c | 2/38 (5%)d | 1/38 (3%) | ND | 3.56 | 3/38 (8%) | |
| Non-ribavirin treated | Kim, 2006e | 24/61 (39%) | 23/61 (38%) | 9.3f | 10.8f | 1/68 |
| 7.6g | 4.7g | |||||
| Lee (1999)h | 60% | 40% | 7–12 | ND | 2–7% | |
| Lee (1999)i | 20/40 (50%) | 8/40 (20%) | ND | ND | 0/40 (0%) | |
| Bruno et al. (1990)j | 18/26 (69%) | 4/26 (16%) | ND | ND | 3/26( 12%) |
Cr = serum creatinine; ND = no data.
Treatment cohort of 34 individuals (excludes four individuals who received ≤three doses of IV ribavirin).
Individual was oliguric before IV ribavirin initiation.
Total cohort of 38 individuals (includes four individuals who received ≤three doses of IV ribavirin).
Both individuals oliguric on day 0 ribavirin (one individual received only three doses of IV ribavirin due to transfer to another hospital for dialysis and is not included in the treatment cohort),
ROK troops hospitalized for HFRS.
Patients who developed oliguria.
Patients who did not develop oliguria.
HFRS from Hantaan virus.
HFRS from Seoul virus.
US military troops who acquired HFRS in Korea.